Findings underscore strength of Natera’s technology for early cancer detection (ECD) Earlier in 2025, Natera reported preliminary AA performance data from a pilot study with 18% sensitivity and 91% ...
Hosted on MSN
Natera announces data from PROCEED-CRC trial
Natera (NTRA) announced another readout for its ECD program, which is evaluating a blood-based screening test for the detection of CRC and advanced adenomas. This latest analysis from the U.S. based, ...
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity Findings underscore strength of Natera’s technology for early ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback